Mar 26, 2026 05:15PM
Sep 10, 2025 08:01AM
Sep 10, 2025 08:00AM
Aug 13, 2025 05:00PM
Jul 8, 2025 08:01AM
Jul 8, 2025 08:00AM
May 14, 2025 09:00AM Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Apr 15, 2025 08:35AM
Apr 15, 2025 08:30AM
Mar 27, 2025 08:01AM
Mar 27, 2025 08:00AM
Mar 17, 2025 04:16PM
Mar 4, 2025 08:03AM
Feb 25, 2025 07:59AM Dermata (DRMA) Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis
Feb 25, 2025 07:58AM
Jan 29, 2025 04:05PM
Jan 21, 2025 08:03AM
Jan 21, 2025 08:00AM
Dec 16, 2024 09:00AM
Dec 10, 2024 09:08AM
Dec 10, 2024 09:00AM Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne
Dec 3, 2024 09:00AM
Nov 13, 2024 04:15PM
Jul 17, 2024 09:00AM
Mar 21, 2024 04:05PM
Dec 20, 2023 04:05PM
Nov 16, 2023 01:34PM
Nov 16, 2023 08:00AM Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
Nov 16, 2023 12:00AM
Nov 9, 2023 04:05PM
Aug 10, 2023 04:15PM
Jun 27, 2023 09:03AM
Jun 27, 2023 09:00AM
Jun 8, 2023 09:03AM
Jun 8, 2023 09:00AM Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
May 11, 2023 04:05PM
Apr 20, 2023 06:01AM
Apr 20, 2023 06:00AM
Feb 21, 2023 04:05PM
Dec 5, 2022 08:36AM
Dec 5, 2022 08:30AM
Nov 10, 2022 05:20PM Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Aug 15, 2022 04:05PM
May 16, 2022 04:05PM
Mar 28, 2022 08:30AM
Nov 15, 2021 04:01PM

322,199 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All